Main Street Financial Solutions LLC Purchases 453 Shares of Hologic, Inc. (NASDAQ:HOLX)

Main Street Financial Solutions LLC increased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 14.0% during the 3rd quarter, Holdings Channel reports. The firm owned 3,683 shares of the medical equipment provider’s stock after buying an additional 453 shares during the period. Main Street Financial Solutions LLC’s holdings in Hologic were worth $300,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of HOLX. Prentiss Smith & Co. Inc. lifted its holdings in Hologic by 0.3% in the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after buying an additional 130 shares during the period. Covestor Ltd boosted its holdings in Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 133 shares in the last quarter. Massmutual Trust Co. FSB ADV increased its position in Hologic by 20.3% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 831 shares of the medical equipment provider’s stock valued at $62,000 after purchasing an additional 140 shares during the period. Wedmont Private Capital increased its position in Hologic by 3.7% during the 3rd quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock valued at $361,000 after purchasing an additional 162 shares during the period. Finally, Sequoia Financial Advisors LLC raised its holdings in Hologic by 2.3% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock worth $536,000 after purchasing an additional 165 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of HOLX stock opened at $77.54 on Friday. The company has a market capitalization of $18.01 billion, a price-to-earnings ratio of 23.29, a price-to-earnings-growth ratio of 2.52 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67. The company’s 50-day moving average is $80.77 and its 200 day moving average is $78.22.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. The company had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.89 earnings per share. Sell-side analysts expect that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday. Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Hologic in a report on Tuesday, October 15th. Stephens restated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. JPMorgan Chase & Co. upped their price target on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, Mizuho lowered their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and an average target price of $89.91.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.